DrugPatentWatch Database Preview
Drugs in Development Information for Masitinib
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Masitinib?
Masitinib is an investigational drug.
There have been 31 clinical trials for Masitinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Mastocytosis, and Sclerosis. The leading clinical trial sponsors are AB Science and [disabled in preview].
There are sixteen US patents protecting this investigational drug and one hundred and eighty-nine international patents.
Summary for Masitinib
| US Patents | 16 |
| International Patents | 189 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 67 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-06-01) |
| Vendors | 75 |
Recent Clinical Trials for Masitinib
| Title | Sponsor | Phase |
|---|---|---|
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | AB Science | Phase 3 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | AB Science | Phase 3 |
| Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels | AB Science | Phase 3 |
Clinical Trial Summary for Masitinib
Top disease conditions for Masitinib
Top clinical trial sponsors for Masitinib
US Patents for Masitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Masitinib | Start Trial | Fusion proteins and methods thereof | The Trustees of Columbia University in the City of New York (New York, NY) | Start Trial |
| Masitinib | Start Trial | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | AB SCIENCE (Paris, FR) | Start Trial |
| Masitinib | Start Trial | 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases | AB Science (Paris, FR) | Start Trial |
| Masitinib | Start Trial | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors | AB Science (Paris, FR) | Start Trial |
| Masitinib | Start Trial | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB Science (Paris, FR) | Start Trial |
| Masitinib | Start Trial | Anti-IGF antibodies | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | Start Trial |
| Masitinib | Start Trial | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB Science (Paris, FR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Masitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Masitinib | Australia | 2014236947 | 2033-03-15 | Start Trial |
| Masitinib | Canada | 2907152 | 2033-03-15 | Start Trial |
| Masitinib | European Patent Office | 2968551 | 2033-03-15 | Start Trial |
| Masitinib | Japan | 2016515508 | 2033-03-15 | Start Trial |
| Masitinib | South Korea | 20150129847 | 2033-03-15 | Start Trial |
| Masitinib | World Intellectual Property Organization (WIPO) | 2014151734 | 2033-03-15 | Start Trial |
| Masitinib | Argentina | 092899 | 2032-10-04 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
